Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer by unknown
Dent et al. Breast Cancer Research 2013, 15:R88
http://breast-cancer-research.com/content/15/5/R88RESEARCH ARTICLE Open AccessPhase I trial of the oral PARP inhibitor olaparib
in combination with paclitaxel for first- or
second-line treatment of patients with
metastatic triple-negative breast cancer
Rebecca A Dent1,2*, Geoffrey J Lindeman3, Mark Clemons4, Hans Wildiers5, Arlene Chan6, Nicole J McCarthy7,
Christian F Singer8, Elizabeth S Lowe9, Claire L Watkins10 and James Carmichael10,11Abstract
Introduction: This Phase I study evaluated the safety, tolerability and efficacy of olaparib, a potent oral poly(ADP-
ribose) polymerase (PARP) inhibitor, in combination with paclitaxel in patients with metastatic triple-negative breast
cancer (mTNBC).
Methods: Eligible patients who had received ≤1 prior cytotoxic regimen for mTNBC were treated with olaparib 200 mg
bid continuously plus weekly paclitaxel 90 mg/m2 for three weeks per four-week cycle. Dose modifications in a
large proportion of patients due to neutropenia resulted in enrollment of a second cohort of patients who, if they
experienced grade ≥2 neutropenia in cycle 1, received granulocyte-colony stimulating factor, which was
continued prophylactically in subsequent cycles. All patients had measurable disease; tumor responses were
evaluated according to RECIST (version 1.0).
Results: Nineteen patients (cohort 1, n = 9; cohort 2, n = 10) received treatment; 15 had received prior taxane
chemotherapy. The most frequent adverse events were diarrhea (n = 12, 63%), nausea (n = 11, 58%) and
neutropenia (n = 11, 58%). Seven neutropenia events were reported in cohort 1 (four grade ≥3) and four in cohort
2 (two grade ≥3, including one event of febrile neutropenia). The median (range) dose intensity of paclitaxel was
57% (26 to 100%) in cohort 1 and 73% (29 to 100%) in cohort 2. Seven patients (37%) had a confirmed partial
response; one patient remains on olaparib monotherapy without progression.
Conclusions: The combination of olaparib and weekly paclitaxel was complicated by a significant clinical
interaction, with higher-than-expected rates of neutropenia despite secondary prophylaxis. Given the encouraging
response rate, alternative scheduling and dosing strategies should be considered (funded by AstraZeneca;
ClinicalTrials.gov, NCT00707707).Introduction
Triple-negative breast cancers (TNBC) are defined by the
lack of expression of the estrogen receptor (ER), proges-
terone receptor (PR) and human epidermal growth factor
receptor 2 (HER2) [1]. TNBC has distinct clinical and
pathological characteristics and occurs at higher rates in
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reproduction in any medium, provided the ordescent [2,3]. Advanced TNBC confer an aggressive clin-
ical course with a poor prognosis compared with other
breast cancer subtypes. Most notably, patients who
present with TNBC have a median survival of 7 to 13
months following recurrence, compared with greater than
20 months for patients with non-TNBC [4,5].
It is now recognized that TNBC is molecularly heteroge-
neous and there are ongoing efforts to define appropriate
targets for directed therapy. With no confirmed single
oncogenic driver, TNBC is not amenable to treatment
with currently approved targeted approaches, such asd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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treatment the main systemic treatment option. Evidence
from studies of taxane-based chemotherapy regimens have
indicated that patients with TNBC derive greater benefit
from regimens that include a taxane than those that do not
[6-8].
One of the first molecular insights into TNBC is the ob-
servation that a significant proportion of tumors arise in
BRCA1 mutation carriers and have gene expression pro-
files that are similar to those of BRCA-deficient tumors
[9]. The BRCA1 gene plays a critical role in DNA double-
strand break repair, contributing to the maintenance of
DNA stability. Poly(ADP-ribose) polymerase (PARP) en-
zymes, especially PARP-1, are critical for appropriate rec-
ognition and repair of DNA breaks. Tumor cell lines
lacking functional BRCA1 or BRCA2 (most notably defects
in homologous recombination) have been shown to be
sensitive to PARP inhibitors in preclinical studies [10,11].
Demonstrating proof-of-principle, studies of olaparib, a po-
tent oral PARP inhibitor, have demonstrated monotherapy
activity and acceptable toxicity in patients with ovarian or
breast cancer who have a germline BRCA1 or BRCA2 mu-
tation [12,13]. However, in the subset of patients with a
germline BRCA1 or BRCA2 mutation who participated in
a Phase II study of olaparib monotherapy, no confirmed
objective responses were observed in the eight patients
with breast cancer [14].
Given the similarities between BRCA1-associated breast
cancers and TNBC, it has been suggested that TNBC may
be sensitive to therapeutic strategies that target DNA re-
pair mechanisms.
In view of the preclinical and early clinical data reporting
efficacy in tumors with homologous recombination defects,
this study was initiated to evaluate the safety and tolerabil-
ity of olaparib in combination with standard weekly pacli-
taxel in patients with metastatic TNBC (mTNBC).
Methods
Patients
Eligible female patients aged >18 years were enrolled at
six centers in four countries. All patients were required
to have histologically or cytologically, locally confirmed
mTNBC (ER- and PR-negative [Allred score <3 or an IHC
score of 0] and HER2-negative [IHC score of 0 or 1, or
fluorescence in situ hybridization (FISH) negative] breast
carcinoma); received ≤1 prior cytotoxic therapy regimen
for metastatic disease; an Eastern Cooperative Group
(ECOG) performance status ≤2; normal organ and bone
marrow function; a minimum washout period of 12 months
following any previous paclitaxel treatment; and a mini-
mum washout period of 2 weeks following any other previ-
ous chemotherapy or radiotherapy.
All patients provided written informed consent. The
study was approved by the independent ethics committeefor each trial center: Melbourne Health Human Research
Ethics Committee, Melbourne, Victoria, Australia; Bellberry
Limited Human Research Ethics Committee, Ashford,
South Australia, Australia; Mount Hospital Ethics Commit-
tee, Perth, Western Australia, Australia; Ethikkommission
Medizinische Universität Wien, Vienna, Austria;
Commissie Medische Ethiek van de Univ. Ziekenhuis K.U.
Leuven, Leuven, Belgium; Ontario Cancer Research Ethics
Board MARs Centre, Toronto, Ontario, Canada. The study
was conducted in accordance with the Declaration of
Helsinki [15], consistent with Good Clinical Practice and
the AstraZeneca policy on bioethics [16].
Study design
This was a Phase I, open-label, multicenter, safety study to
establish the safety and tolerability of olaparib and pacli-
taxel (ClinicalTrials.gov identifier: NCT00707707). A
double-blind, randomized Phase II portion of the study was
planned if an acceptable dose was identified in Phase I.
Patients initially received olaparib 200 mg bid (4 × 50 mg
capsules twice daily) in combination with paclitaxel 90 mg/
m2 administered as an intravenous (iv) infusion over one
hour on days 1, 8 and 15 of a 28-day cycle for 6 to 10 cycles
(cohort 1). This dose of olaparib was chosen following the
assessment of the pharmacokinetic (PK) and safety and tol-
erability profiles of olaparib in human monotherapy studies
at doses of between 100 mg and 400 mg bid (the maximum
tolerated dose) [12,13,17]. Toxicities were managed with
olaparib and paclitaxel dose interruptions, and paclitaxel
dose reductions to 65 mg/m2. After paclitaxel had been ad-
ministered in combination with olaparib for 6 to 10 cycles
at the discretion of the treating physician, paclitaxel was
stopped and olaparib treatment was continued as 400 mg
bid monotherapy until objective disease progression. Toxic-
ities associated with olaparib monotherapy were managed
by dose interruption; in the event of a toxicity recurring
after dose interruption, or if olaparib dosing was
interrupted owing to a grade ≥3 adverse event (AE), dose
reduction to 200 mg bid (and then, if necessary, to 100 mg
bid) was considered or required, respectively.
A greater-than-expected occurrence of grade ≥2 neu-
tropenia within the first two cycles of treatment resulted
in paclitaxel dose modifications, including dose reduc-
tions and dosing delays. Consequently, a second cohort
of patients was enrolled following a protocol amendment
that included a stepwise approach to the management of
neutropenia and allowed the use of prophylactic adminis-
tration of granulocyte colony-stimulating factor (G-CSF)
to enable optimal dose intensity of paclitaxel to be main-
tained. Patients in cohort 2 received olaparib and pacli-
taxel at the same doses and schedule as patients in cohort
1. For patients in cohort 2, upon first occurrence of grade ≥2
neutropenia, the paclitaxel dose was omitted or delayed;
olaparib dosing was continued; and G-CSF 5 μg/kg/day
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solute neutrophil count (ANC) was ≥1.5 × 109/l or for a
maximum of 14 days (Figure 1a). Once ANC was ≥1.5 ×
109/l, then paclitaxel dosing was resumed at full dose and
prophylactic G-CSF was administered in subsequent cy-
cles. However, if ANC remained <1.5 × 109/l after 14 days
of treatment with G-CSF, then olaparib and paclitaxel were
discontinued. Following the first occurrence of grade ≥2
neutropenia, prophylactic G-CSF 5 μg/kg/day sc was ad-
ministered on days 3 to 5, 10 to 12 and 17 to 19 in subse-
quent cycles following paclitaxel dosing on days 1, 8 and
15 (Figure 1b). The management of subsequent treatment
cycles in patients who received rescue G-CSF is depicted
in Figure 1b. In cohort 1, G-CSF was prohibited during
the first cycle of therapy, but permitted thereafter at the
investigator’s discretion for management of neutropenia
according to local hospital guidelines and local clinical
practice. Prophylactic use of G-CSF was discouraged.
A minimum of six evaluable patients were required to
complete two cycles of combination therapy. Therefore,
it was expected that 10 patients per cohort would be re-
quired to ensure 6 evaluable patients.
Study endpoints and assessments
The primary endpoint was evaluation of safety and toler-
ability of olaparib in combination with paclitaxel, assessed
by the incidence and severity of AEs according to Common
Terminology Criteria for Adverse Events (CTCAE) version
3.0. Secondary endpoints were evaluation of preliminary
overall response rate (ORR) and progression-free survival
(PFS) assessed by investigators according to Response
Evaluation Criteria In Solid Tumors (RECIST) version 1.0.
PFS was defined as the time from randomization to the
earliest date of assessment of objective progression (per
RECIST) or death by any cause in the absence of progres-
sion. Efficacy analyses were not originally planned for the
Phase I part of the study, but these endpoints have been
summarized as the study did not proceed into Phase II.
Statistical analysis
Data are summarized descriptively as no formal statistical
comparisons of the data were performed. The Wilson
score method was used to calculate the 90% confidence
intervals (CI), which are provided for preliminary ORR
data as a measure of precision. Median PFS and 95% CIs
were calculated using Kaplan–Meier methodology.
Results
Patients
Of 24 patients enrolled between 15 September 2008 and
21 April 2009, 19 received study treatment (n = 9, co-
hort 1; n = 10, cohort 2). Five patients were not assigned
to treatment due to disease progression (n = 1), screen-
ing failure (n = 3) and voluntary withdrawal (n = 1).Baseline demographics are shown in Table 1; all patients
were female and Caucasian. Five and six patients in co-
horts 1 and 2, respectively, received at least six cycles of
combination therapy and six patients in each cohort
completed at least six cycles of olaparib treatment. Me-
dian actual olaparib treatment duration (excluding dose
interruptions) was 168.0 days (range 50 to 389) in cohort
1 and 151.0 days (range 57 to 243) in cohort 2. Median
dose intensity (total dose received/total dose planned) of
olaparib was 100% (cohort 1 range 86 to 100%; cohort 2
range 80 to 100%) in both cohorts. Median dose inten-
sity (total dose received/total dose planned) of paclitaxel
was 57.2% (range 26 to 100%) in cohort 1 and 73.1%
(range 29 to 100%) in cohort 2. At the time of data cut-off
(9 November 2009), one patient in cohort 1 was ongoing
(receiving olaparib only) and three patients in cohort 2
were ongoing (two were receiving olaparib plus paclitaxel
and one olaparib only); one patient in cohort 2, who is not
a BRCA1/2 mutation carrier, was in complete radiological
remission and still receiving olaparib in December 2012.
Safety
All 19 patients experienced at least one AE. The majority
of patients (16 (84%)) experienced at least one AE that
was considered to be related to olaparib treatment. Thir-
teen patients (68%) had at least one CTCAE grade ≥3
event, and a greater proportion of these were in cohort 1
(89%) than cohort 2 (50%).
The most frequently reported CTCAE grade ≥3 events
were neutropenia (44%) and anemia (22%) in cohort 1 and
neutropenia (20%) in cohort 2 (Table 2). Seven (78%) and
nine (90%) patients in cohorts 1 and 2, respectively, expe-
rienced AEs that were considered to be related to olaparib
treatment, the most commonly reported were neutropenia
(53%), diarrhea (42%), fatigue (37%) and nausea (26%). All
19 patients experienced AEs that were considered to be
causally related to paclitaxel, the most common of which
were neutropenia (58%), fatigue (53%), alopecia (53%) and
diarrhea (47%). One patient died in cohort 1 (post follow-
up) due to disease progression and multiple-organ failure.
Treatment dose modifications
Eight patients (89%) in cohort 1 had paclitaxel dose
modifications (dose delay and/or dose reduction), six
(67%) of whom had both a delay and a dose reduction.
Four patients (44%) had olaparib dose modifications
(dose reduction, n = 2; dose delay, n = 2) due to neutro-
penia; one of these patients also had a dose interruption
of olaparib because of infection and anemia, and another
of these four patients had a dose interruption of olaparib
due to skin infection (of the breast) and skin disorder
(skin breakdown).
In cohort 2, six patients (60%) had paclitaxel dose
modifications, with three (30%) having both a delay and
a) First occurrence of 
grade ≥ 2 neutropenia  
G-CSF 5 µg/kg/day rescue initiated
Scheduled paclitaxel dose omitted
or subsequent cycle delayed
Olaparib dosing continued
G-CSF administered until
ANC ≥1.5 x 109 cells/l or for a
maximum of 14 days
Paclitaxel and olaparib
dosing discontinued





ANC <1.5 x 109 cells/lANC ≥1.5 x 109 cells/l
b)
G-CSF, granulocyte colony-stimulating factor; ANC, absolute neutrophil count
Prophylactic G-CSF administered on days 3 to 5,
10 to12 and 17 to19 of the 28-day cycle with
paclitaxel on days 1, 8 and 15
Continue olaparib dosing
Continue paclitaxel and olaparib
dosing with prophylactic G-CSF
Resume paclitaxel monotherapy
90 mg/m 2
G-CSF to be used
if clinically indicated
Once ANC ≥1.5 x 109 cells/l
resume paclitaxel at reduced
dose 65 mg/m 2
G-CSF to be used
if clinically indicated
ANC <1.5 x 109 cells/l at date
of scheduled paclitaxel dosing
ANC <1.5 x 109 cells/l at 
date of scheduled dosing
ANC <1.5 x 109 cells/l 
after 7 days dose delay
ANC <1.5 x 109 cells/l 
after 14 days dose delay
Paclitaxel dose delayed 
>28 days, ANC <1.5 x 109 cells/l
ANC ≥1.5 x 109 cells/l
ANC ≥1.5 x 109 cells/l
ANC ≥1.5 x 109 cells/l
ANC ≥1.5 x 109 cells/l
Paclitaxel dose
delayed <28 days
No further treatment with paclitaxel
and olaparib in combination
No further treatment with paclitaxel
Omit paclitaxel dosing
Interrupt olaparib dosing for 7 days
Omit paclitaxel dosing (if due)
Interrupt olaparib dosing for a further 7 days
     
Figure 1 Management of (a) the first occurrence of neutropenia using rescue G-CSF and (b) subsequent treatment cycles in patients
who have received rescue G-CSF in cohort 2.
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Table 1 Baseline demographics
Cohort 1 Cohort 2 Overall
(n = 9) (n = 10) (n = 19)
Mean age,
years (range)
50.0 (36 to 71) 50.7 (38 to 67) 50.4 (36 to 71)
ECOG status, n






5 (56) 9 (90) 14 (74)
Taxanea 7 (78) 8 (80) 15 (79)
First-line setting 2 (22) 0 2 (11)
Adjuvant setting 2 (22) 6 (60) 8 (42)
Neo-adjuvant setting 3 (33) 1 (10) 4 (21)
Metastatic
setting
0 2 (20) 2 (11)
Anthracycline 6 (67) 6 (60) 12 (63)
Capecitabine 1 (11) 0 1 (5)
ECOG, Eastern Cooperative Group.
aOne patient in cohort 2 had previously received taxane chemotherapy in
both adjuvant and metastatic settings.
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modifications; two patients (20%) due to neutropenia
with one of these patients also undergoing dose modifi-
cations of olaparib due to pyrexia, herpes zoster and
aphasia. The other patient had dose modifications of
olaparib due to increased blood bilirubin, abnormal
blood lactate dehydrogenase and abnormal gamma-
glutamyltransferase.Table 2 Adverse events reported by ≥30% of patients overall
Cohort 1
(n = 9)
Grade 1/2 Grade ≥3
Diarrhea 6 (67) 0
Nausea 5 (56) 0
Neutropenia 3 (33) 4 (44)a
Alopecia 6 (67) 0
Fatigue 6 (67) 0
Anemia 3 (33) 2 (22)
Constipation 4 (44) 0
Peripheral neuropathy 3 (33) 0
Rash 1 (11) 0
Vomiting 3 (33) 0
aIncludes one grade 4 event.
bIncludes one case of febrile neutropenia.Efficacy
ORR in cohort 1 was 3/9 patients (33.3%, 90% CI; 14.2
to 60.2%) and in cohort 2 was 4/10 patients (40%, 90%
CI; 19.4 to 64.8%; Table 3). Median PFS (95% CI) was
6.3 (3.5 to 8.9) months for cohort 1 and 5.2 (3.5 - not
calculable) months for cohort 2 (Figure 2). These esti-
mated medians are based on very few events (six in each
cohort) so should be interpreted with caution.
Discussion
Current treatment options for TNBC are limited and
there is no standard of care for patients with mTNBC
who have progressed following treatment with standard
chemotherapeutic regimens [18]. The use of PARP in-
hibitors to target DNA repair deficiencies in combin-
ation with systemic therapies continues to generate
considerable clinical interest.
Previously, olaparib 400 mg bid monotherapy led to
promising clinical outcomes in a proof-of-principle trial
in patients with BRCA-deficient breast cancers, despite
prior data suggesting that 100 mg bid might be sufficient
to inhibit PARP [13,19]. We chose an olaparib dose of
200 mg bid for use in combination with standard pacli-
taxel dosing. In the Phase I run-in component of our
study, which was performed to ensure safe delivery of
olaparib with paclitaxel, the combination had a generally
manageable toxicity profile in patients with TNBC. How-
ever, despite this patient cohort not being heavily pre-
treated and not having excessive bone marrow involve-
ment, the treatment combination was associated with a
greater-than-expected incidence and severity of neutro-
penia, which resulted in delivery of a lower paclitaxel
dose intensity than planned. Although the administration, by maximum reported grade
Evaluable patients, n (%)
Cohort 2 Overall
(n = 10) (n = 19)
Grade 1/2 Grade ≥3
6 (60) 0 12 (63)
6 (60) 0 11 (58)
2 (20) 2 (20)b 11 (58)
4 (40) 0 10 (53)
3 (30) 1 (10) 10 (53)
1 (10) 0 6 (32)
2 (20) 0 6 (32)
3 (30) 0 6 (32)
5 (50) 0 6 (32)
3 (30) 0 6 (32)
Table 3 Response rates according to RECIST
Evaluable patients, n (%)
Responder status Cohort 1 Cohort 2
(n = 9) (n = 10)
ORR 3 (33) 4 (40)
CR 0 0b
PRa 3 (33) 4 (40)
SD ≥7 weeks 3 (33) 3 (30)
Unconfirmed PRa 1 (11) 2 (20)
PD 3 (33) 3 (30)
ORR, objective response rate; CR, complete response; PR, partial response; SD,
stable disease; PD, progressive disease.
aOne patient in cohort 1 and two patients in cohort 2 had unconfirmed partial
responses and so were included in the SD seven or more weeks
response category.
bFollowing data cut-off, one patient in cohort 2 achieved a CR and, as of
December 2012, remained in complete radiological remission; no mutation in
the BRCA1 and/or BRCA2 genes was identified in this patient by sequencing
and multiplex ligation-dependent probe amplification (MLPA).
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crease in paclitaxel dose intensity (median intensity 73%
vs 57% in cohort 1), the paclitaxel dose was still lower
than anticipated and the rate of neutropenia remained
high (20%). A suitable dosing schedule could not be iden-
tified for the Phase II part of our study; therefore, the



























Time from first dose (months)
Cohort 1 (no G-CSF)
6.3 (3.5 to 8.9) months








Cohorts were recruited sequentially
NC, not calculable; PFS, progression-free survival





















Time from first dose (months)
Cohort 2 (G-CSF)
5.2 (3.5 to NC) months
Median PFS (95% CI)
Figure 2 Kaplan–Meier curves of progression-free survival in
cohorts 1 and 2.Historically, single-agent paclitaxel in the metastatic
setting has demonstrated much lower rates of grade 3/4
neutropenia (from 0.3% as a first-line treatment to 15%
in heavily pre-treated patients) than observed in combin-
ation with olaparib in our study [20,21]. Dose-limiting
toxicities of myelosuppression have been noted in studies
of other PARP inhibitors in combination with chemother-
apy agents [22-26]. In addition, thrombocytopenia and
neutropenia were the most common grade ≥3 toxicities in
a Phase II trial of the PARP inhibitor veliparib, in com-
bination with the oral alkylating agent temozolomide in
patients with metastatic breast cancer [27]. Olaparib has
previously been evaluated in combination with chemo-
therapy in patients with BRCA1/2-mutant cancer or spor-
adic cancer; the majority of these trials involved treatment
combinations that were expected to be synergistic due to
their effects on DNA repair and hence potentiate mye-
lotoxicity. In a Phase I dose-finding study of olaparib in
combination with carboplatin, the initial continuous
schedule of olaparib dosing was changed to intermittent
administration because of thrombocytopenia and delayed
recovery of neutropenia [28]. However, the combination
of olaparib 200 mg bid with carboplatin and paclitaxel was
recently shown to have an acceptable tolerability profile in
a Phase II trial in patients with serous ovarian cancer [29].
The current study evaluated the combination of olaparib
and paclitaxel, which was not expected to potentiate mye-
lotoxicity. Potential confounders to explain the toxicity
profile experienced by patients in our study include phar-
macodynamic and PK interactions, such as the timing and
sequencing of chemotherapy with olaparib or off-target ef-
fects through inhibition of tankyrases [30]. It is not yet clear
whether neutropenia is potentially a surrogate for clinical
activity. The combination of olaparib with paclitaxel is cur-
rently being evaluated in patients with gastric cancer
(ClinicalTrials.gov identifier: NCT01063517) and advanced
solid tumors (ClinicalTrials.gov identifier: NCT00516724).
Despite the decreased paclitaxel dose intensity in our
study, encouraging response rates were observed follow-
ing treatment with olaparib plus paclitaxel with 3/9 pa-
tients (33%) and 4/10 patients (40%) in cohorts 1 and 2,
respectively, achieving partial responses. Our response
rates are higher than those reported in both a Phase II
study of paclitaxel monotherapy in women with meta-
static breast cancer (21.5%; n = 38/177) and a recent
study of olaparib monotherapy, in which no confirmed
responses were observed among the 23 evaluable pa-
tients with advanced metastatic or recurrent breast can-
cer [14,21]. The response rates in our study are also
notable given the heterogeneous nature of TNBC and
the limited treatment options for this disease. From this
small study, the subtypes of patients with TNBC who are
most likely to respond to olaparib treatment could not
be evaluated; however, responses to olaparib have been
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ovarian cancers with germline BRCA1 and/or BRCA2
mutations, as well as patients with high-grade serous
ovarian cancers, suggesting that there is a subgroup
who will be likely to benefit [12-14]. Future studies
should assess the mutation status of each patient to fur-
ther identify those who are most likely to respond to this
treatment strategy. In addition, future studies should
incorporate other molecular measures of functional
homologous recombination deficiency for their sensi-
tivity to PARP inhibition [31].
Conclusion
In summary, although the incidence of neutropenia ob-
served in our study was higher than would be expected
with either olaparib or paclitaxel alone, the combination
of olaparib and paclitaxel had a generally manageable
toxicity profile and preliminary evidence of antitumor
activity was observed. The optimal schedule of olaparib
administration in combination with paclitaxel was not
defined in this study, leading to its early termination.
The ongoing trials of olaparib in combination with pacli-
taxel should help to identify a suitable treatment sched-
ule for this combination. Currently, it remains unclear
whether the best use of PARP inhibitors will be in com-
bination with another type of DNA-damaging agent, or
with a standard cytotoxic chemotherapy agent to achieve
optimal benefit in patients with TNBC. Therefore, further
studies investigating the safety and efficacy of olaparib
in combination with DNA-damaging agents, cytotoxic
chemotherapy and as a monotherapy are indicated in
this setting.
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